ダウンロード数: 253
このアイテムのファイル:
ファイル | 記述 | サイズ | フォーマット | |
---|---|---|---|---|
dom.13267.pdf | 552.21 kB | Adobe PDF | 見る/開く |
完全メタデータレコード
DCフィールド | 値 | 言語 |
---|---|---|
dc.contributor.author | Harashima, Shin ichi | en |
dc.contributor.author | Inagaki, Nobuya | en |
dc.contributor.author | Kondo, Kazuoki | en |
dc.contributor.author | Maruyama, Nobuko | en |
dc.contributor.author | Otsuka, Makiko | en |
dc.contributor.author | Kawaguchi, Yutaka | en |
dc.contributor.author | Watanabe, Yumi | en |
dc.contributor.alternative | 原島, 伸一 | ja |
dc.contributor.alternative | 稲垣, 暢也 | ja |
dc.date.accessioned | 2018-07-24T04:06:45Z | - |
dc.date.available | 2018-07-24T04:06:45Z | - |
dc.date.issued | 2018-07 | - |
dc.identifier.issn | 1462-8902 | - |
dc.identifier.uri | http://hdl.handle.net/2433/232840 | - |
dc.description.abstract | Sodium‐glucose co‐transporter‐2 (SGLT2) inhibitors and glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) are antihyperglycaemic agents with weight‐lowering effects. The efficacy and safety of the SGLT2 inhibitor canagliflozin as add‐on therapy in Japanese patients with type 2 diabetes mellitus (T2DM) and inadequate glycaemic control with a GLP‐1RA (≥12 weeks) were evaluated in this phase IV study. Patients received canagliflozin 100 mg once daily for 52 weeks. Efficacy endpoints included change in glycated haemoglobin (HbA1c), fasting plasma glucose (FPG), body weight, systolic blood pressure (SBP) and HDL cholesterol from baseline to week 52. Safety endpoints included adverse events (AEs), hypoglycaemia and laboratory tests. Of the 71 patients treated with canagliflozin, 63 completed the study. At 52 weeks, HbA1c was significantly reduced from baseline (−0.70%; paired t test, P < .001). Significant changes were also observed in FPG (−34.7 mg/dL), body weight (−4.46%), SBP (−7.90 mm Hg), and HDL cholesterol (7.60%; all P < .001). The incidence of AEs, adverse drug reactions and hypoglycaemia was 71.8%, 32.4% and 9.9%, respectively. All hypoglycaemic events were mild. These findings suggest that the long‐term combination of canagliflozin with a GLP‐1RA is effective and well tolerated in Japanese patients with T2DM. | en |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Blackwell Publishing Ltd | en |
dc.rights | © 2018 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd. | en |
dc.rights | This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. | en |
dc.subject | Canagliflozin | en |
dc.subject | GLP-1 receptor agonist | en |
dc.subject | Phase IV | en |
dc.subject | SGLT2 inhibitor | en |
dc.subject | Type 2 diabetes | en |
dc.title | Efficacy and safety of canagliflozin as add-on therapy to a glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52-week, open-label, phase IV study | en |
dc.type | journal article | - |
dc.type.niitype | Journal Article | - |
dc.identifier.jtitle | Diabetes, Obesity and Metabolism | - |
dc.identifier.volume | 20 | - |
dc.identifier.issue | 7 | - |
dc.identifier.spage | 1770 | - |
dc.identifier.epage | 1775 | - |
dc.relation.doi | 10.1111/dom.13267 | - |
dc.textversion | publisher | - |
dc.address | Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine | en |
dc.address | Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine | en |
dc.address | Ikuyaku Integrated Value Development Division, Mitsubishi Tanabe Pharma CorporationTokyo | en |
dc.address | Ikuyaku Integrated Value Development Division, Mitsubishi Tanabe Pharma CorporationTokyo | en |
dc.address | Ikuyaku Integrated Value Development Division, Mitsubishi Tanabe Pharma CorporationTokyo | en |
dc.address | Ikuyaku Integrated Value Development Division, Mitsubishi Tanabe Pharma CorporationTokyo | en |
dc.address | Ikuyaku Integrated Value Development Division, Mitsubishi Tanabe Pharma CorporationTokyo | en |
dc.identifier.pmid | 29473709 | - |
dcterms.accessRights | open access | - |
出現コレクション: | 学術雑誌掲載論文等 |
このリポジトリに保管されているアイテムはすべて著作権により保護されています。